{
  "pattern_name": "maximal_stability",
  "description": "Maximum stability pattern for in vivo applications",
  "reference": "Based on FDA-approved siRNA therapeutics (Onpattro, Givlaari)",
  "guide_modifications": {
    "2OMe": {
      "positions": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21],
      "strategy": "all_positions",
      "rationale": "Complete 2'-O-methyl modification provides maximum nuclease resistance"
    },
    "PS": {
      "positions": "dinucleotides",
      "internucleotide_linkages": [[1, 2], [2, 3], [19, 20], [20, 21]],
      "rationale": "Phosphorothioate linkages at terminal dinucleotides provide additional stability"
    }
  },
  "passenger_modifications": {
    "2OMe": {
      "positions": [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21],
      "strategy": "all_positions",
      "rationale": "Complete modification prevents passenger strand activity"
    },
    "PS": {
      "positions": "dinucleotides",
      "internucleotide_linkages": [[1, 2], [2, 3]],
      "rationale": "5' terminal PS linkages reduce passenger strand loading"
    }
  },
  "overhang": {
    "guide_3prime": "dTdT",
    "passenger_3prime": "dTdT",
    "rationale": "DNA overhangs with PS modifications if needed"
  },
  "estimated_properties": {
    "serum_stability_half_life_hours": 72,
    "relative_synthesis_cost": 3.0,
    "nuclease_resistance": "very-high",
    "risc_loading_efficiency": "high",
    "recommended_for": "in_vivo, therapeutic_development"
  },
  "notes": [
    "Pattern similar to FDA-approved therapeutic siRNAs",
    "Suitable for in vivo efficacy and toxicology studies",
    "Higher cost justified for therapeutic development",
    "May require lipid nanoparticle or GalNAc delivery",
    "Consult with synthesis provider for feasibility"
  ],
  "fda_approved_examples": [
    {
      "drug_name": "Patisiran (Onpattro)",
      "target": "TTR",
      "approval_year": 2018,
      "indication": "Hereditary transthyretin amyloidosis"
    },
    {
      "drug_name": "Givosiran (Givlaari)",
      "target": "ALAS1",
      "approval_year": 2019,
      "indication": "Acute hepatic porphyria"
    }
  ]
}
